UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024
24. September 2024 08:00 ET
|
Unity Biotechnology, Inc.
UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024
UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)
21. Juni 2023 07:00 ET
|
Unity Biotechnology, Inc.
Phase 2b trial is a randomized, double-masked, active-controlled study designed to evaluate the safety and efficacy of UBX1325 (foselutoclax) compared to aflibercept over 24 weeks First novel...
UNITY Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease
14. Februar 2022 08:00 ET
|
Unity Biotechnology, Inc.
24-week UBX1325 Phase 1 data presented at Angiogenesis, Exudation, and Degeneration 2022 Conference Patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD)...
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
21. April 2021 08:00 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases...
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Business Updates
23. März 2021 16:01 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of...
UNITY Biotechnology to Participate in Upcoming March Investor Conferences
26. Februar 2021 16:05 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of...
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
24. Februar 2021 08:00 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of...
Study published in Cell Metabolism Reveals New Therapeutic Approach Aimed at Restoring Vascular Health and Reversing Age-Related Eye Disease
08. Februar 2021 08:00 ET
|
Unity Biotechnology, Inc.
Study shows that senescent cells accumulate in the eye of patients with diabetic retinopathy, and elimination of these cells in preclinical models ameliorates disease Researchers at UNITY...
UNITY Biotechnology Appoints Mike Sapieha, Ph.D., as Chief Scientific Advisor
01. Februar 2021 08:00 ET
|
Unity Biotechnology, Inc.
Mike Sapieha brings world-class expertise in aging-related ophthalmologic and neurologic diseases UNITY also names Jason Damiano, Ph.D., as vice president of translational biology and Nathan Guz,...
UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology
15. September 2020 08:00 ET
|
Unity Biotechnology, Inc.
- Corporate restructuring to extend cash runway through mid-2022 and key milestones - - UBX1325 to enter clinical development in patients with diabetic macular edema - SAN FRANCISCO, Calif., Sept. ...